Table 2.

HCRU and costs during the 12 months prior to the index date^a

All-cause HCRU, mean (SD)
Number of hospitalizations	1.7 (3.2)
Length of inpatient stays in days	16.1 (30.8)
Number of emergency room visits	0.6 (1.1)
Number of outpatient visits	88.5 (107.7)
Number of pharmacy fills	42.5 (19.6)
All-cause total healthcare costs, mean (SD) b	$439,871 ($272,509)
MM-related HCRU, mean (SD)
Number of hospitalizations	1.4 (2.7)
Length of inpatient stays in days	15.4 (30.6)
Number of emergency room visits	0.2 (0.4)
Number of outpatient visits	69.9 (84.8)
MM-related healthcare costs, mean (SD) b
Inpatient cost	$51,097 ($131,615)
Emergency room cost	$449 ($1,230)
Outpatient cost	$58,850 ($68,016)
MM drug cost	$263,600 ($170,639)
MM drug infusion cost	$11,705 ($12,004)
Stem cell transplant cost	$24,893 ($71,356)
Other costs	$3,730 ($2,460)
Total costs	$414,323 ($260,961)

HCRU healthcare resource utilization, LOT line of therapy, MM multiple myeloma, SD standard deviation, TCE triple class exposure

^aIndex date, defined as the initiation date of first LOT post-TCE

^bAverage cost for all patients in the sample; patients may not have incurred a cost in every category